Business
Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":"\n\nRevenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States.\n\n\n\nRevenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States.\n\n\n\nThe Company’s year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025.\n\n\n\n NEW YORK--(BUSINESS WIRE)--\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025.\n\n\nEstablishment Labs’ preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 million to $17.5 million from Motiva sales in the United States. Based on the expected range for fourth quarter revenue, Establishment Labs expects full-year 2025 revenue of $210.5 million to $211.5 million, an increase of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company’s year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. The preliminary financial results have yet to be audited and are subject to change.\n\n\n“We had an excellent finish to 2025, with record quarterly revenue,” said Peter Caldini, Establishment Labs’ Chief Executive Officer. “Growth will continue in 2026 as our business accelerates towards being the industry standard. We continue to have positive adjusted EBITDA, and our cash position reflects our success in managing and improving the business. We expect to turn free cash flow positive later this year, and our operating leverage will become very evident in 2026 and beyond. I look forward to our meetings at the J.P. Morgan Healthcare Conference this week and presenting our full 2025 results on our February earnings call.”\n\n\nAbout E...